DeciBio Ventures flags pharma services sector push into AI-enabled clinical development in Q3 2026 roundup

PUBT · 2d ago
DeciBio Ventures flags pharma services sector push into AI-enabled clinical development in Q3 2026 roundup
  • DeciBio Ventures’ Q3 2026 pharma services round-up flagged accelerating AI adoption across clinical development platforms.
  • ICON entered a multi-year collaboration with Anthropic to embed Claude into Orbis for trial operations, including site selection.
  • Samsung Biologics launched an all-cash tender offer of $1.8 billion for PolyPeptide, targeting peptide capacity tied to GLP-1 demand.
  • Tempus AI agreed to acquire Personalis to add MRD testing, tightening integration across its precision oncology platform.
  • Fortrea agreed to buy Worldwide’s early phase services unit for $45 million, expanding early-stage capabilities via lab and clinic assets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DeciBio Ventures published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.